Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

76.40 USD -0.03 (-0.04%)
Official Closing Price Updated: 5:19 PM EDT, Apr 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week
Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week 
From Business Wire News Releases
AavantiBio Deepens AAV Manufacturing Capabilities with Key Hires to Support Strategic Growth
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced new additions to its leadership team with the appointments of Paul Herzich... 
From Business Wire News Releases
Organon Announces Pricing of Senior Notes Offering
Organon Announces Pricing of Senior Notes Offering. 
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
Merck’s KEYTRUDA Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With RCC Following Surgery 
From Business Wire News Releases
Organon Announces Proposed Senior Notes Offering
Organon Announces Proposed Senior Notes Offering 
From Business Wire News Releases
Merck Completes Acquisition of Pandion Therapeutics
Merck Completes Acquisition of Pandion Therapeutics 
From Business Wire News Releases
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon 
From Business Wire News Releases
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Uro
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® To Include Results of Phase 3 KEYNOTE-361 Trial in Urothelial Cancer 
From Business Wire News Releases
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application for KEYTRUDA in High-Risk Early-Stage TNBC 
From Business Wire News Releases
Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
Merck to hold First-Quarter 2021 Sales and Earnings Conference Call on April 29 
From Business Wire News Releases
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Merck Appoints Caroline Litchfield Chief Financial Officer
Merck Appoints Caroline Litchfield Chief Financial Officer 
From Business Wire News Releases
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophage
FDA Approves Merck’s KEYTRUDA Plus Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or GEJ Carcinoma 
From Business Wire News Releases
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Pr
KEYTRUDA Plus LENVIMA Significantly Improved Progression-Free Survival and Overall Survival vs Chemo in Patients With Advanced Endometrial Cancer 
From Business Wire News Releases
Merck Named One of the 2021 Best Workplaces in Health Care and Biopharma™ by Great Place to Work® and Fortune
Tags Corporate Social Responsibility NYSE:MRK Diversity & Inclusion
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.
Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co. 
From Business Wire News Releases
European Commission Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
European Commission Approves Expanded Indication for KEYTRUDA in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma 
From Business Wire News Releases
Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health
Mike Nally to leave Merck; Frank Clyburn to lead all Merck Human Health 
From Business Wire News Releases
Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)
Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482) 
From Business Wire News Releases
How the COVID-19 Pandemic Has Shined a Light on Mental Health and Sparked a Movement to Change the Way We Work
Tags Employee Engagement Partnerships Women
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead
Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead 
From Business Wire News Releases
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that they have entered into an agreement to co-develop and... 
From Business Wire News Releases
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
USA News Group - Rollouts of two approved COVID-19 vaccines have for the past few months started making their way into markets around the world. Amid the attention given to COVID vaccines, new vaccines... 
From PR Newswire
Drexel Solutions Institute and Merck Launch Leadership Program for Diverse Suppliers
Tags Corporate Governance Education Merck
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
From GlobeNewswire News Releases
Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021
Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021 
From Business Wire News Releases
Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment for Adults with Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
From PR Newswire
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account